Aurobindo Pharma
AUROPHARMA.NS
#1875
Rank
NZ$15.22 B
Marketcap
$26.22
Share price
0.76%
Change (1 day)
29.54%
Change (1 year)

P/E ratio for Aurobindo Pharma (AUROPHARMA.NS)

P/E ratio as of December 2024 (TTM): 36.1

According to Aurobindo Pharma 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 36.0739. At the end of 2022 the company had a P/E ratio of 12.9.

P/E ratio history for Aurobindo Pharma from 2012 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202212.9-14.29%
202115.050.1%
202010.00-4.16%
201910.4-43.95%
201818.612.74%
201716.5-1.93%
201616.8-38.33%
201527.338.06%
201419.834.75%
201314.7-22.03%
201218.8

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.